SCHEMBL710510

SCHEMBL710510

C(/C=C/c1ccco1)=C\c1ccccn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.52
NPC1 O15118 6/20 0.52
RAB9A P51151 4/20 0.52
PKM P14618 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
LMNA P02545 2/20 0.52
NPSR1 Q6W5P4 1/20 0.52
MEN1 O00255 6/20 0.52
ATM Q13315 2/20 0.52
MAPT P10636 7/20 0.50
KDM4E B2RXH2 7/20 0.50
L3MBTL1 Q9Y468 6/20 0.50
TDP1 Q9NUW8 5/20 0.50
POLB P06746 4/20 0.50
RECQL P46063 4/20 0.50
BLM P54132 3/20 0.50
CTDSP1 Q9GZU7 2/20 0.50
ALDH1A1 P00352 5/20 0.49
HTT P42858 2/20 0.49
MCL1 Q07820 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL710511 1.00 KMT2A (0.52) KMT2ANPC1RAB9APKMSMN1; SMN2
SCHEMBL708569 0.98 KMT2A (0.51) KMT2ANPC1RAB9APKMSMN1; SMN2
SCHEMBL708568 0.98 KMT2A (0.51) KMT2ANPC1RAB9APKMSMN1; SMN2
SCHEMBL28255358 0.89 KMT2A (0.61) KMT2ANPC1RAB9APKMSMN1; SMN2
SCHEMBL29000592 0.89 KMT2A (0.61) KMT2ANPC1RAB9APKMSMN1; SMN2
SCHEMBL721182 0.80 MEN1 (0.79) KMT2ANPC1RAB9APKMLMNA
SCHEMBL9298131 0.80 F2 (0.67) KMT2ANPC1RAB9ASMN1; SMN2LMNA
SCHEMBL721181 0.80 MEN1 (0.79) KMT2ANPC1RAB9APKMLMNA
SCHEMBL9298138 0.80 F2 (0.67) KMT2ANPC1RAB9ASMN1; SMN2LMNA
SCHEMBL708571 0.78 MEN1 (0.75) KMT2ANPC1RAB9APKMLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124625-B2 enhancing the expression of apoAI; prevention or therapy of dislipidemia SHIONOGI & CO., LTD. (JP) 2012-02-28 US disclosed
US-8053445-B2 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2011-11-08 US disclosed
US-20090036457-A1 Utilities of olefin derivatives YAMAMORI TERUO 2009-02-05 US disclosed
US-20040242615-A1 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242615-A1 Utilities of olefin derivatives APOL1, NR1H2, APOB KMT2A 3382/4885NPC1 19/4885RAB9A 4723/4885
US-20090036457-A1 Utilities of olefin derivatives APOL1, APOB, NR1H2 KMT2A 3744/4885NPC1 48/4885RAB9A 4606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.